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1. Introduction 
Acute myeloid leukemia (AML) is a neoplastic disorder characterized by the clonal 
expansion of non-lymphoid hematopoietic progenitor cells with failure of normal 
hematopoiesis. Several biological and clinical parameters have been identified at diagnosis 
to classify different AML subtypes with different prognosis. In this view, genetic 
abnormalities confer the most important prognostic information. Therapeutic interventions 
based on conventional or high-dose chemotherapy have significantly improved the 
complete remission (CR) rates of acute leukemia. However, a significant portion of 
responding patients still harbors a minimal residual disease (MRD), which is often resistant 
to further pharmacological treatments and ultimately leads to disease relapse and 
progression. Although allogeneic stem cell transplantation may significantly improve the 
clinical results of AML patients who achieved complete remission, such approach has 
several and important limitations and is not applicable to all the patients. For these reasons, 
novel therapeutic approaches to improve the clinical outcome of AML patients are under 
investigation, and treatments with high compliance such as adoptive and active 
immunotherapy are desirable. Aim of the present work will be to focus the most relevant 
insights in the field. In particular, we will report about the use of natural killer (NK) cells as 
a means of adoptive immunotherapy against neoplastic cells, including AML. Moreover, we 
will discuss the role of vaccines against leukemia with particular emphasis on the 
immunogenicity of novel and promising leukemia-associated antigens. 
2. Acute Myeloid Leukemia 
Acute myeloid leukemia (AML) is a hematopoietic malignant disease rising from neoplastic 
transformation of myeloid stem cells. This causes the alteration of the normal cell 
differentiation and proliferation systems, resulting in the accumulation in bone marrow and 
peripheral blood of non-functional myeloid cells termed myeloblasts. AML may arise de 
novo or secondary to pre-existing myelodysplasia or previous chemotherapies.  
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Myeloblasts lack the normal proliferation systems and their over-proliferation and 
accumulation in bone marrow and peripheral blood cause lack of production of 
hematopoietic normal cells, this resulting in peripheral deficiency of platelets, neutrophils 
and hemoglobin. 
Prognosis of AML depends on multiple factors: age at diagnosis (age>60 years is a poor 
prognostic factor), hyperleukocytosis, cytogenetic status and molecular specific 
characteristics are the most important ones. 
AML can occur at every age, but its incidence increases with age (median age at 
presentation: 65 years). It has an annual incidence of 3.6 per 100,000.  This incidence 
increases with age, rising to 16.3 per 100,000 per year in the over 65 age group. Older adults 
typically have a highly inferior prognosis and an increased risk of therapy-related toxicity 
and mortality. 
Conventional treatment of AML is based on chemotherapy regimens and consists of several 
well-defined phases: the first one is the CR-induction cycle, based on the administration of 3 
days-anthacycline associated with 7 days-cytarabine. Its aim is to ‘empty’ bone marrow and 
allow the normal hematopoietic cells repopulation.  
Response rates with conventional chemotherapy range from 60% to 85% in young adults 
(age < 60 years), but more than 50% of these patients are going to relapse, with a five-year 
overall survival of 40%. Older patients with a diagnosis of AML have a poorer prognosis, 
with less than 10% of long survivers; this is due to biological unfavorable risk factors, such 
as unfavorable cytogenetics, which are more frequent in the elderly (Leith et al. 1997). 
One of the main cause of relapse in patients who achieved complete remission after 
chemotherapy is the persistance of a small amount of leukemic cells termed MRD. Minimal 
residual disease detection became one of the main tasks for hematologists;  
immunophenotypical and molecular markers able to discriminate normal cells from blastic 
cells allow the detection of residual leukemic cells not detected by morphologic 
examinations. 
After the induction therapy two or more consolidation cycles are needed in order to 
eradicate leukemic cells completely. Allogeneic stem cell transplantation is one of the most 
effective consolidation therapy, even if it is feasible only for fit patients and only if a suitable 
HLA-matched donor is available.  
Moreover, allogeneic stem cell transplantation is highly effective if performed after 
obtaining first CR, while its efficacy is poor in case of relapsed/refractory patients. 
Only young and fit patients can undergo stem cell transplantation because of its 
significantly high toxicity, mortality and morbidity rates. 
Attempts to effectively prime and sustain anti-tumor immunity against leukemic cells have 
recently provided promising preclinical and clinical results. Results from allogeneic stem 
cell transplantation (SCT) represent the main evidence that leukemic cells are targets of the 
immune system. In fact, since the first clinical observation that allogeneic SCT offered a 
clinical advantage over autologous transplantation due to a graft-versus-leukemia (GVL) 
effect, much more attention has been given to the role of adoptive immunotherapy over 
conditioning regimen as a means to eradicate tumor cells. In particular, donor lymphocyte 
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infusions (DLIs) are capable to restore a durable complete remission. Such results are the 
proof of principle of the crucial activity of anti-tumor immunity in controlling the growth of 
leukemic cells.  
3. Adoptive immunotherapy with natural killer cells 
Human NK cells are a subset of PB lymphocytes defined by the expression of CD56 or CD16 
and the absence of the T-cell receptor (CD3) (Robertson et al, 1990). They recognize and kill 
transformed cell lines in an MHC-unrestricted fashion and play a critical role in the innate 
immune response. Several studies demonstrated that NK function, which is distinct from 
the MHC-restricted cytolytic activity of T cells, may be relevant for the immune control of 
tumor development and growth. Although NK cell killing is MHC-unrestricted, NK cells 
display a number of activating and inhibitory receptors that ligate MHC molecules to 
modulate the immune response (Lanier et al, 1998). NK cell receptors that recognize 
antigens at the HLA-A, -B, or -C loci are members of the immunoglobulin super family and 
are termed killer immunoglobulin receptors or KIRs (Farad et al, 2002). Engagement of these 
NK cell receptors results in stimulation or inhibition of NK cell effector function, which 
ultimately depends on the net effect of activating and inhibitory receptors (Figure 1).  
 
Clinical trials attempting to utilize the anti-tumor effect of NK cells have met only modest 
success due to the lack of understanding of receptors and ligands which determine whether 
NK cells will be activated or suppressed. On the contrary, data from haploidentical T-cell 
depleted transplantation suggest that KIR mismatch with tumor MHC may significantly 
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impact on tumor cell killing, particularly in AML (Ruggeri et al, 2002). In fact, these studies 
show that AML patients with KIR ligand mismatch are significantly protected against 
leukemia relapse. In addition, preclinical and clinical investigations demonstrated that 
haploidentical KIR-mismatched NK cells play the main role as anti-leukemia effector cells 
and they exert their cytotoxic activity within 4-5 days (Ruggeri et al 2002, Ruggeri et al, 
1999). In particular, high risk AML patients with a KIR-ligand mismatch in the graft-versus-
host (GVDH) direction had a relapse rate of 0% compared to KIR-ligand matched patients 
who had a relapse rate of 75%. Given these results, haploidentical KIR-mismatch NK cells 
administered to AML patients as cell-based immunotherapy may induce NK cell-mediated 
killing of leukemia cells resulting in the elimination of residual disease in high risk AML 
patients. Furthermore, alloreactive mismatched NK cells facilitate hematopoietic 
engraftment after infusion of haploidentical stem cells, and inhibit the onset of GVHD by 
targeting host antigen-presenting cells (Ruggeri et al, 2002). Of note, the differential 
expression of activating ligands on hematopoietic and not hematopoietic tissues may 
provide an additional explanation for the observed GVL effect in the absence of GVHD. 
Partially purified haploidentical NK cells have been already used clinically and labeled with 
111In to track, in vivo, their kinetics and organ distribution in patients with renal cancer 
(Brand et al, 2004). A seminal study demonstrated that up to 1.5 x 107/haploidentical NK 
cells/Kg can be safely infused in AML and cancer patients following Fludarabine/ 
Cyclophosphamide (Flu/Cy) immunosuppressive chemotherapy and, in some cases, clinical 
responses without GVHD had been observed (Miller et al, 2005). Interestingly, circulating 
haploidentical NK cells were found, in selected patients, up to 28 days after infusion 
especially when exogenous IL-2 was given for 9 doses. In vivo expansion of NK cells was 
correlated with a high IL-15 serum concentration. In particular, in this study, 19 poor risk 
AML patients were reported who had received a cell population containing a median of 
8.50.5 X 106 and 1.750.3 X 105 NK and T cells, respectively. Five out of 19 patients achieved 
CR. NK cells adoptive immunotherapy was well tolerated and hematological and non 
hematological toxicity were mainly related to the immunosuppressive regimen and IL-2 
administration. The maximum tolerated dose of NK cells was not achieved and GVHD was 
not observed despite the relatively high number of haploidentical T cells infused. However, 
it should be noted that NK cells were only partially purified after a single round of 
depletion of CD3+ cells which resulted in less than 2 logs reduction of T cells.   
More recently, a study of haploidentical KIR-HLA mismatched NK cell transplantation in 
childhood AML reported that NK cell therapy  prolonged disease-free and overall 
survival (Rubnitz et al, 2010). In this pediatric cohort of AML patients, who underwent 
NK therapy after an  immunosuppressive regimen, the 2-year event-free survival was 
100%. Notably, all the children were considered at low-risk of relapse, with a significant 
fraction harboring good-prognosis cytogenetics. Furthermore, as children weigh less than 
adults, the median number of infused NK cells  was significantly higher than in adult trial 
and the separation procedure consisted in highly purified NK cells. These differences may 
partially explain the discrepancy in clinical results and suggest that in adult patients the 
clinical effect of NK therapy may be implemented by increasing the number of infused 
NK cells.  
We recently published the results of a clinical trial of adoptive immunotherapy with 
haploidentical KIR-mismatched NK cells in elderly patients with AML (Curti et al, 2011). 
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Thirteen AML patients, 5 with active disease, 2 in molecular relapse and 6 in morphological 
complete remission (CR);(median age 62 years, range 53-73) received highly purified 
CD56+CD3- NK cells from haploidentical KIR-ligand mismatched donors after fludarabine/ 
cyclophosphamide immunosuppressive chemotherapy, followed by IL-2. The median 
number of infused NK cells was 2.74 x 106/Kg. T cells were under 105/Kg. No NK cell-
related toxicity, including GVHD, was observed. One of the 5 patients with active disease 
achieved transient CR, whereas 4/5 patients had no clinical benefit. Both patients in 
molecular relapse achieved CR which lasted for 9 and 4 months, respectively. Three/6 
patients in CR are disease-free after 34, 32 and 18 months. After infusion, donor NK cells 
were found in the peripheral blood of all evaluable patients (peak value on day 10). They 
were also detected in bone marrow in some cases. Donor-versus-recipient alloreactive NK 
cells were demonstrated in vivo by the detection of donor-derived NK clones that killed 
recipient’s targets. Adoptively transferred NK cells were alloreactive against recipient’s 
cells, including leukemia. Taken together, these data demonstrate that infusion of purified 
NK cells is feasible in elderly patients with high risk AML. 
4. Vaccination against acute myeloid leukemia: WT1 as a novel promising 
antigen 
During the last years a number of studies have demonstrated that tumor-associated antigens 
(TAA) may be recognized by the immune system leading to the activation of tumor-specific 
cytotoxic T lymphocytes (CTLs) with the potential to eradicate tumor cells. Moreover, 
during the last decade the role of dendritic cells (DCs) as natural adjuvants of immune 
response has been deeply elucidated. The identification of a wide number of TAA, together 
with new insights into the mechanisms underlying the activation of anti-tumor immune 
response, has led to the development of novel anti-tumor vaccination strategies which are 
currently under investigation in the clinical setting. In AML, some TAA, such as PRAME, 
Wilms’ tumor gene (WT1), proteinase 3 have been recently identified. In particular, WT1, 
which  is a zinc-finger transcription factor expressed during normal ontogenesis, is 
significantly over-expressed in acute and chronic myeloid leukemia and myelodysplastic 
syndromes and it appears as an attractive target for immunotherapy.   
WT1-specific antibodies against the N-terminus portion of the WT1 protein have been found 
in the sera of AML patients, but not in healthy donors, suggesting that anti-WT1-specific 
immune response is present in these patients. Preclinical studies have clearly demonstrated 
that peptides from WT1 may be used to generate in vitro a WT1-specific cytotoxic response 
(Li et al, 2005; Pinilla-Ibarz et al, 2006; Oka et al, 2000). While a number of WT1-derived CD8 
T-cell epitopes have been reported, two peptides, namely HLA-A0201-restricted peptide 
126–134 and HLA-A24-restricted peptide 235–243, have been studied extensively. Since 
murine and human WT1 are similar, WT1 126 and WT1 235 have also been tested in animal 
models. B6 mice were injected with WT1 peptides and analyzed for the induction of a T-cell 
and B-cell mediated immune responses against WT1. This analysis revealed that WT1 
vaccination induced WT1-specific immunity, which was also capable to delay in vivo the 
growth of tumor cell lines, naturally overexpressing WT1. Recently, a National Cancer 
Institute Pilot Project assigned to WT1 the position of best and most suitable target antigen 
for cancer immunotherapy, due to a number of characteristics, such as its therapeutic 
function, immunogenicity and expression level (Cheever et al, 2009) 
www.intechopen.com
 
Hematology – Science and Practice 494 
These data have prompted several groups to investigate the role of WT1 as a tumor-antigen 
in the clinical setting of cancer immunotherapy. Particularly, Oka et al conducted phase I 
clinical trials using peptide WT1-235 (CMTWNQMNL) and its analogue (CYTWNQMNL) 
for patients with overt leukemia from MDS, MDS with myelofibrosis and AML (Oka et al, 
2004). Vaccination was performed by injecting 0.3–3 mg of native or analogue peptide 235 
emulsified with the adjuvant Montanide ISA51. The vaccination resulted in an increase in 
WT1-specific CTLs followed by a rapid reduction in leukemic blast cells. No serious toxicity 
was observed, but leukemic blasts relapsed after the vaccination was stopped.  Recently, 
these investigators reported that biweekly injection of AML patients with either native or 
analogue peptide 235 along with Montanide and GM-CSF resulted in three patients 
remaining in CR for 4 years (Tsuboi et al, 2007). The WT1-235 peptide has also been shown 
to induce HLA-A0201-restricted CTL (Pinilla-Ibarz, 2006). Keilholz et al first reported that 
vaccination of a patient with recurrent AML, using HLA-A0201-restricted WT1 peptide 126 
along with KLH as an adjuvant, induced CR (Mailander et al, 2004). No haematological or 
renal toxicities were observed. Rezvani et al reported a phase I clinical trial in patients with 
AML, CML and MDS, using combined HLA-A0201-binding peptide vaccines from PR1 169–
177 and WT1 126–134. Their results show that the emergence of PR1+ or WT1+CD8+ T cells 
in patients who received WT1 vaccine was associated with a decrease in WT1 mRNA 
expression, suggesting a vaccine-driven anti-leukemia effect (Rezvani et al, 2008). An 
analogue to WT1 peptide 126–134 was generated by substituting R for Y at the position 2 
anchor motif (named WT1-A1) (Pinilla-Ibarz et al, 2006). This analogue peptide generated a 
more potent CD8 T-cell response which recognized and lysed WT1+ leukemia cells in vitro. 
In addition to the HLA-A0201 and -A24 vaccines derived from WT1 protein, Asemissen et al 
identified a highly immunogenic HLA-A1-binding WT1 peptide (317–327) that is processed 
and able to induce a CD8 T-cell response in healthy donors and patients with 
haematological malignancies (Asemissen et al, 2006).  
The German group reported about their phase 2 trial of WT1 peptide vaccination in patients 
with AML and MDS (Keilholz et al, 2009). Vaccination consisted of GM-CSF subcutaneously 
days 1 to 4, and WT1126-134 peptide and 1 mg keyhole limpet hemocyanin on day 3. 
Seventeen AML patients and 2 refractory anemia with excess blasts patients received a 
median of 11 vaccinations. Treatment was well tolerated. Objective responses in AML 
patients were 10 stable diseases (SDs) including 4 SDs with more than 50% blast reduction 
and 2 with hematologic improvement. An additional 4 patients had clinical benefit after 
initial progression, including 1 CR and 3 SDs. WT1 mRNA levels decreased at least 3-fold 
from baseline in 35% of patients. In 8 of 18 patients, WT1-tetramer+ T cells increased in 
blood and in 8 over 17 patients in bone marrow, with a median frequency in bone marrow 
of 0.18% at baseline and 0.41% at week 18. This WT1 vaccination study provides 
immunologic, molecular, and preliminary evidence of potential clinical efficacy in AML 
patients, warranting further investigations.  
Other approaches include the use of autologous DCs, generated from leukemia patients in 
CR and loaded with tumor antigens and/or the differentiation of leukaemia blasts into 
leukemic DCs. In particular, Van Tendeloo et al reported the results of a phase I/II clinical 
trial of WT1 vaccination based on antigen-loaded DCs with the induction of complete and 
molecular responses in some cases (Van Tendeloo et al, 2010). These results are promising. 
However, the clinical experience with DC-based vaccines targeting WT1 is far too limited 
and future studies are highly warranted to assess the role and the efficacy of these strategies 
of active immunotherapy in the clinical management of MRD in AML.  
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5. Conclusion 
In conclusion, the clinical results of AML patients, especially if elderly, are particularly 
dismal, although the achievement of CR with MRD after combined chemotherapy appears 
as possible in the majority of patients. Unfortunately, the persistence of MRD leads to 
progression and patients ultimately die. For these reasons, alternative approaches for the 
prevention of relapse in CR patients are necessary and are currently under active 
investigation. In particular, the role of immunological therapies in the post-remission 
management of adult AML patients, such as NK therapy and active immunization against 
relevant tumor rejection antigens, including WT1, have been recently exploited with 
promising results in terms of immunological and clinical responses. Further studies (phase 
II-III) are highly warranted to really evaluate the role of such approaches and their impact 
on overall survival of AML patients.  
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